Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis

European Journal of Ophthalmology

Volumn 19, Issue 3, 2009, Pages 331-336

  Russo, Vincenzo ^a   Stella, Andrea ^a   Appezzati, Loredana ^a   Barone, Antonio ^a   Stagni, Edoardo ^b   Roszkowska, Anna M ^c   Noci, Nicola Delle ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Ginkgo biloba extract; Hyaluronic acid; Seasonal allergic conjunctivitis

Indexed keywords

GINKGO BILOBA EXTRACT; HYALURONIC ACID; TRIUM; UNCLASSIFIED DRUG; EYE DROPS; GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

ADOLESCENT; APPLICATION SITE REACTION; APPLICATION SITE STINGING; ARTICLE; CHEMOSIS; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISCHARGE; FEMALE; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OUTCOME ASSESSMENT; PHOTOPHOBIA; PRIORITY JOURNAL; SCORING SYSTEM; SEASONAL ALLERGIC CONJUNCTIVITIS; TREATMENT DURATION; ALLERGIC CONJUNCTIVITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GINKGO BILOBA; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; CONJUNCTIVITIS, ALLERGIC; DRUG THERAPY, COMBINATION; FEMALE; GINKGO BILOBA; HUMANS; HYALURONIC ACID; MALE; OPHTHALMIC SOLUTIONS; PLANT EXTRACTS; TREATMENT OUTCOME;

EID: 66149100430     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900301     Document Type: Article

References (20)

1. Bonini S, Magrini L, Rotiroti G, et al. The eosinophil and the eye. Allergy 1997; 52: 693-7.
2. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005; 115: 118-22.
3. Anderson DF, MacLeod JD, Baddeley SM, et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin Exp Allergy 1997; 27: 1060-6.
4. Woodward DF, Nieves AL, Hawley SB, et al. The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J Ocul Pharmacol Ther 1995; 11: 339-47.
5. Strachan D, Sibbald B, Weiland S, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8: 161-76.
6. Anderson DF. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies. Clin Exp Allergy 2001; 31: 823-6.
7. Nathan P. Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology? Med Hypoth 2000; 55: 491-3.
8. Luo Y, Smith JV. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004; 64: 465-72.
9. Thiagarajan G, Chandani S, Harinarayana Rao S, et al. Molecular and cellular assessment of Ginkgo biloba extract as a possible ophthalmic drug. Exp Eye Res 2002; 75: 421-30.
10. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327-32.
11. Köse K, Doǧan P. Lipoperoxidation induced by hydrogen peroxide in human erythrocyte membranes. 2. Comparison of the antioxidant effect of Ginkgo biloba extract (EGb 761) with those of water-soluble and lipid-soluble antioxidants. J Int Med Res 1995; 23: 9-18.
12. Ahlemeyer B, Möwes A, Krieglstein J. Inhibition of serum deprivation-and staurosporine-induced neuronal apoptosis by Ginkgo biloba extract and some of its constituents. Eur J Pharmacol 1999; 367: 423-30.
13. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86: 181-4.
14. Gomes JA, Amankwah R, Powell-Richards A, Dua HS. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br J Ophthalmol 2004; 88: 821-5.
15. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125: 797-804.
16. Juniper EF, Guyatt GH, Ferrie PJ, King DR. Sodium cromoglycate eye drops: regular versus "as needed" use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunol 1994; 94: 36-43.
17. Abelson MB, Chapin MJ, Kapik BM, Shams NB. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol 2003; 121: 626-30.
18. Lloves J, Montero Iruzubieta J, Sainz De La Maza Serra MT, Fuster Jensen E, Lladonosa Montull A. Effectiveness and impact in the quality of life of ketotifen ophthalmic solution. Results of zeta study in patients with seasonal allergic conjunctivitis. Arch Soc Esp Oftalmol 2003; 78: 433-41.
19. Ciprandi G, Buscaglia S, Cerqueti MP, et al. Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivitis: a comparative double-blind study. J Invest Allergol Clin Immunol 1992; 2: 248-52.
20. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11: 478-83.